Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma

European Journal of Surgical Oncology

Volumn 38, Issue 4, 2012, Pages 333-339

  Robinson, S M ^a   Rahman, A ^a   Haugk, B ^b   French, J J ^a   Manas, D M ^a   Jaques, B C ^a   Charnley, R M ^a   White, S A ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Lymph node; Metastases; Pancreatic ductal adenocarcinoma; Pancreaticoduodenectomy

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DUODENUM CARCINOMA; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUROENDOCRINE TUMOR; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; UNIVARIATE ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; ENGLAND; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 84857914802     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2011.12.020     Document Type: Article

References (43)

1. UK CR. Cancerstats key facts pancreatic cancer. [cited 4 March 2010]; Available from: http://info.cancerresearchuk.org/prod-consump/groups/cr-common/ @nre/@sta/documents/generalcontent/crukmig-1000ast-3075.pdf.
2. T.A. Sohn, C.J. Yeo, and J.L. Cameron Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators J Gastrointest Surg 4 6 2000 Nov-Dec 567 579
3. M.H. Katz, H. Wang, and J.B. Fleming Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma Ann Surg Oncol 16 4 2009 Apr 836 847
4. N.A. Ahmad, J.D. Lewis, and G.G. Ginsberg Long term survival after pancreatic resection for pancreatic adenocarcinoma Am J Gastroenterol 96 9 2001 Sep 2609 2615
5. S.P. Cleary, R. Gryfe, and M. Guindi Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors J Am Coll Surg 198 5 2004 May 722 731 (Pubitemid 38542900)
6. K.F. Kuhlmann, S.M. de Castro, and J.G. Wesseling Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients Eur J Cancer 40 4 2004 Mar 549 558 (Pubitemid 38220772)
7. C.R. Ferrone, M.F. Brennan, and M. Gonen Pancreatic adenocarcinoma: the actual 5-year survivors J Gastrointest Surg 12 4 2008 Apr 701 706
8. J.L. Cameron, T.S. Riall, J. Coleman, and K.A. Belcher One thousand consecutive pancreaticoduodenectomies Ann Surg 244 1 2006 Jul 10 15 (Pubitemid 44297442)
9. C.P. Raut, J.F. Tseng, and C.C. Sun Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma Ann Surg 246 1 2007 Jul 52 60 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov′t] (Pubitemid 47012207)
10. J.M. Winter, J.L. Cameron, and K.A. Campbell 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience J Gastrointest Surg 10 9 2006 Nov 1199 1210 discussion 210-1
11. J.E. Lim, M.W. Chien, and C.C. Earle Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients Ann Surg 237 1 2003 Jan 74 85 (Pubitemid 36622320)
12. C.S. Verbeke, D. Leitch, K.V. Menon, M.J. McMahon, P.J. Guillou, and A. Anthoney Redefining the R1 resection in pancreatic cancer Br J Surg 93 10 2006 Oct 1232 1237 (Pubitemid 44547022)
13. J.W.C. Chen, M. Bhandari, and D.S. Astill Predicting patient survival after pancreaticoduodenectomy for malignancy: histopathological criteria based on perineural infiltration and lymphovascular invasion HPB 12 2 2010 101 108
14. J. Neoptolemos, M. Buchler, and D.D. Stocken ESPAC-3(v2): a multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma J Clin Oncol 27 Suppl. 18 2009 abstract LBA4505
15. J.P. Neoptolemos, D.D. Stocken, and C. Tudur Smith Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials Br J Cancer 100 2 2009 Jan 27 246 250
16. J.P. Neoptolemos, J.A. Dunn, and D.D. Stocken Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial Lancet 358 9293 2001 Nov 10 1576 1585 (Pubitemid 33101907)
17. W.F. Regine, K.A. Winter, and R.A. Abrams Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial JAMA 299 9 2008 Mar 5 1019 1026 (Pubitemid 351347058)
18. M.H. Katz, R. Hwang, J.B. Fleming, and D.B. Evans Tumor-node-metastasis staging of pancreatic adenocarcinoma CA Cancer J Clin 58 2 2008 Mar-Apr 111 125 (Pubitemid 351521866)
19. A.C. Berger, J.C. Watson, E.A. Ross, and J.P. Hoffman The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma Am Surg 70 3 2004 Mar 235 240 discussion 40
20. F. Petrelli, K. Borgonovo, and S. Barni The emerging issue of ratio of metastatic to resected lymph nodes in gastrointestinal cancers: an overview of literature Eur J Surg Oncol 2011 Aug 13
21. L.L. Tong, P. Gao, and Z.N. Wang Can lymph node ratio take care, the place of pN categories in the UICC/AJCC TNM classification system for colorectal cancer? Ann Surg Oncol 18 9 2011 Sep 2453 2460
22. C.M. Huang, J.X. Lin, and C.H. Zheng Prognostic impact of metastatic lymph node ratio on gastric cancer after curative distal gastrectomy World J Gastroenterol 16 16 2010 Apr 28 2055 2060
23. T.M. Pawlik, A.L. Gleisner, and J.L. Cameron Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer Surgery 141 5 2007 May 610 618 (Pubitemid 46616937)
24. M.B. Slidell, D.C. Chang, and J.L. Cameron Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis Ann Surg Oncol 15 1 2008 Jan 165 174
25. Exocrine pancreas F. Greene, D. Page, I. Fleming, A. Fitz, C. Balch, and D. Haller AJCC cancer staging manual 6 ed 2002 Springer Verlag
26. F. Campbell, M. Bennett, and A. Foulis Minimum dataset for histopathological reporting of pancreatic, ampulla of vater and bile duct carcinoma 1 ed. 2002 Royal College of Pathologist London
27. G. Kloppel, G. Lingenthal, M. von Bulow, and H.F. Kern Histological and fine structural features of pancreatic ductal adenocarcinomas in relation to growth and prognosis: studies in xenografted tumours and clinico- histopathological correlation in a series of 75 cases Histopathology 9 8 1985 Aug 841 856 (Pubitemid 15228591)
28. R.E. Schwarz, and D.D. Smith Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database Ann Surg Oncol 13 9 2006 Sep 1189 1200 (Pubitemid 44440420)
29. M. Hellan, C.L. Sun, and A. Artinyan The impact of lymph node number on survival in patients with lymph node-negative pancreatic cancer Pancreas 37 1 2008 Jul 19 24
30. F. Cordera, C.A. Arciero, T. Li, J.C. Watson, and J.P. Hoffman Significance of common hepatic artery lymph node metastases during pancreaticoduodenectomy for pancreatic head adenocarcinoma Ann Surg Oncol 14 8 2007 Aug 2330 2336 (Pubitemid 47174906)
31. S. Connor, L. Bosonnet, and P. Ghaneh Survival of patients with periampullary carcinoma is predicted by lymph node 8a but not by lymph node 16b1 status Br J Surg 91 12 2004 Dec 1592 1599 (Pubitemid 39619923)
32. J.P. Neoptolemos, D.D. Stocken, and J.A. Dunn Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial Ann Surg 234 6 2001 Dec 758 768 (Pubitemid 33117196)
33. K.V. Menon, D. Gomez, A.M. Smith, A. Anthoney, and C.S. Verbeke Impact of margin status on survival following pancreatoduodenectomy for cancer: the leeds pathology protocol (LEEPP) HPB (Oxford) 11 1 2009 Feb 18 24
34. I. Esposito, J. Kleeff, and F. Bergmann Most pancreatic cancer resections are R1 resections Ann Surg Oncol 15 6 2008 Jun 1651 1660
35. N.B. Jamieson, S.M. Denley, and J. Logue A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma Ann Surg Oncol 2011 Jan 26
36. C.S. Verbeke, and K.V. Menon Redefining resection margin status in pancreatic cancer HPB (Oxford) 11 4 2009 Jun 282 289
37. H. Riediger, T. Keck, and U. Wellner The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer J Gastrointest Surg 13 7 2009 Jul 1337 1344
38. M.G. House, M. Gonen, and W.R. Jarnagin Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer J Gastrointest Surg 11 11 2007 Nov 1549 1555
39. S. Pedrazzoli, V. DiCarlo, and R. Dionigi Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group Ann Surg 228 4 1998 Oct 508 517 (Pubitemid 30194394)
40. M.B. Farnell, G.V. Aranha, Y. Nimura, and F. Michelassi The role of extended lymphadenectomy for adenocarcinoma of the head of the pancreas: strength of the evidence J Gastrointest Surg 12 4 2008 Apr 651 656
41. C.J. Yeo, J.L. Cameron, and K.D. Lillemoe Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality Ann Surg 236 3 2002 Sep 355 366 discussion 66-8
42. D.J. Gouma, R.C. van Geenen, and T.M. van Gulik Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume Ann Surg 232 6 2000 Dec 786 795
43. S. Mukherjee, H.M. Kocher, R.R. Hutchins, S. Bhattacharya, and A.T. Abraham Impact of hospital volume on outcomes for pancreaticoduodenectomy: a single UK HPB centre experience Eur J Surg Oncol 35 7 2009 Jul 734 738